Intermittent bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains viral suppression in real life in controlled HIV-infected patients

被引：0
|
作者：
Sellem, B. [1 ]
Abdi, B. [2 ]
Peytavin, G. [3 ]
Tubiana, R. [1 ]
Valantin, M. -A. [1 ]
Seang, S. [1 ]
Schneider, L. [1 ]
Faycal, A. [1 ]
Soulie, C. [2 ]
Marcelin, A. -G. [2 ]
Katlama, C. [1 ]
Pourcher, V. [1 ]
Palich, R. [1 ]
机构：
[1] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Infect Dis Dept,INSERM 1136, Pierre Louis Epidemiol & Publ Hlth Inst iPLESP, Paris, France
[2] Sorbonne Univ, Pitie Salpetriere Hosp, AP HP,Virol Dept,INSERM 1136, Pierre Louis Epidemiol & Publ Hlth Inst iPLESP, Paris, France
[3] Univ Paris, Bichat Claude Bernard Hosp, AP HP, Pharmacol Toxicol Dept,IAME,INSERM,UMRS 1137, Paris, France
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/23
引用
收藏
页码：90 / 91
页数：2
相关论文
共 50 条
  • [31] Efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir combinations in HIV-1 adult population: A systematic review and meta-analysis
    Biju, Anto Amith J.
    Shaju, Aina
    Mudigubba, Manoj Kumar
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 325 - 326
  • [32] Bictegravir-based antiretroviral therapy in HIV-1 group O patients: data from real-life bictegravir/emtricitabine/tenofovir alafenamide switches
    Martin, Charlene
    Unal, Guillemette
    Plantier, Jean-Christophe
    Alessandri-Gradt, Elodie
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (08) : 2305 - 2307
  • [33] Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China
    Kong, Linghong
    Xie, Xiaoxin
    Fu, Yanhua
    Gan, Lin
    Yang, Xiaoyan
    Ma, Shujing
    Long, Hai
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (08)
  • [34] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
    Podzamczer, Daniel
    Imaz, Arkaitz
    Lopez-Lirola, Ana
    Knobel, Hernando
    Masia, Mar
    Fanciulli, Chiara
    Hernandez, Cristina
    Lagarde, Maria
    Gutierrez, Angela
    Curran, Adria
    Morano, Luis
    Montero-Alonso, Marta
    Troya, Jesus
    Rigo, Raul
    Casadella, Maria
    Navarro-Alcaraz, Antonio
    Ardila, Fernando
    Parera, Mariona
    Bernal, Enrique
    Echeverria, Patricia
    Estrada, Vicente
    Hidalgo-Tenorio, Carmen
    Macias, Juan
    Prieto, Paula
    Portilla, Joaquin
    Valencia, Eulalia
    Vivancos, Maria Jesus
    Rivero, Antonio
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (11) : 2696 - 2701
  • [35] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naive people with both HIV-1 and hepatitis B: 3-year outcomes from ALLIANCE
    Avihingsanon, Anchalee
    Lu, Hongzhou
    Leong, Chee Loon
    Hung, Chien-Ching
    Kiertiburanakul, Sasisopin
    Lee, Man-Po
    Supparatpinyo, Khuanchai
    Madera, Sharline
    Wang, Hongyuan
    Hindman, Jason
    Li, Taisheng
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 323 - 324
  • [36] Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG) plus F/TAF or DTG plus F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance
    Acosta, Rima K.
    Willkom, Madeleine
    Andreatta, Kristen
    Liu, Hui
    Martin, Ross
    Parvangada, Aiyappa
    Martin, Hal
    Collins, Sean
    White, Kirsten L.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 85 (03) : 363 - 371
  • [37] Eligibility of patients in a community HIV setting for switching rilpivirine/emtricitabine/tenofovir disoproxil fumarate (R/F/TDF) to tenofovir alafenamide(TAF)
    Goorney, B.
    Perez, K.
    HIV MEDICINE, 2019, 20 : 39 - 39
  • [38] Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients
    Gutierrez-Lorenzo, Marta
    Rubio-Calvo, Daniel
    Urda-Romacho, Joaquin
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2021, 34 (04) : 315 - 319
  • [39] Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis
    Esser, S.
    Stellbrink, H-J
    Heiken, H.
    Meynard, J-L
    Thorpe, D.
    Schreiber, S.
    Heinzkill, M.
    Sahali, S.
    Ramroth, H.
    Haubrich, R.
    HIV MEDICINE, 2019, 20 : 67 - 68
  • [40] High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence
    Andreatta, Kristen
    DAntoni, Michelle L.
    Chang, Silvia
    Parvangada, Aiyappa
    Martin, Ross
    Blair, Christiana
    Hagins, Debbie
    Kumar, Princy
    Hindman, Jason T.
    Martin, Hal
    Callebaut, Christian
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (10)
12345